Blueprint Medicines (BPMC) Reports Q4 Loss, Tops Revenue Estimates
BPMCBlueprint Medicines(BPMC) Zacks Investment Research·2024-02-15 22:26

Blueprint Medicines (BPMC) came out with a quarterly loss of 1.82pershareversustheZacksConsensusEstimateofalossof1.82 per share versus the Zacks Consensus Estimate of a loss of 2.04. This compares to loss of 2.65pershareayearago.Thesefiguresareadjustedfornonrecurringitems.Thisquarterlyreportrepresentsanearningssurpriseof10.782.65 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 10.78%. A quarter ago, it was expected that this cancer drug developer would post a loss of 2.39 per share when it actually produced a loss of $2.20, delivering a surprise of 7.95%. Over the last four quarters, the c ...